Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P49748
UPID:
ACADV_HUMAN
Alternative names:
-
Alternative UPACC:
P49748; B4DEB6; F5H2A9; O76056; Q8WUL0
Background:
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial, catalyzes the initial step of mitochondrial fatty acid beta-oxidation, targeting acyl-CoAs with 12 to 24 carbon chains. This process is crucial for energy production from fats, involving the conversion of fatty acids into acetyl-CoA.
Therapeutic significance:
Acyl-CoA dehydrogenase very long-chain deficiency, a mitochondrial fatty acid beta-oxidation disorder, manifests in varying severities, from severe childhood forms with cardiomyopathy to adult-onset skeletal muscle involvement. Understanding the role of this enzyme could pave the way for novel treatments.